Company / Accounts Receivable
Bionano Genomics, Inc. Accounts Receivable History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$5.2M
FY2025
5-year range
$4.8M / $9.3M
FY2021-FY2025
Trend
+9.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has fluctuated over the past 8 years, ranging from $3M in FY2020 to $9M in FY2023.
Based on SEC 10-K filings.
$5M in FY2025 with a 5-year CAGR of +13.4%.
Declined from $9M to $5M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -9.5%
- 5-Year CAGR
- +13.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +13.4%, indicating consistent growth.
- In FY2025, accounts receivable increased 9.4% year-over-year.
- Peak accounts receivable was recorded in FY2023.
- Lowest accounts receivable in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.2M | +9.4% |
| FY2024 | $4.8M | -49.0% |
| FY2023 | $9.3M | +32.7% |
| FY2022 | $7.0M | +42.3% |
| FY2021 | $4.9M | +77.8% |
| FY2020 | $2.8M | -56.2% |
| FY2019 | $6.3M | +40.3% |
| FY2018 | $4.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026